Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly (LLY) to $1,171 from $1,090 and keeps an Overweight rating on the shares. Following the recently announced GLP-1 pricing and access agreements between the Trump administration, Lilly and Novo (NVO), the firm says its Medicare obesity sensitivity analysis provides its with “additional confidence in our above consensus LLY estimates.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy
- Citigroup Sees 50% Upside in Eli Lilly Stock (LLY)
- Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise
- Eli Lilly initiated with an Outperform at Scotiabank
- Eli Lilly price target raised to $1,500 from $1,250 at Citi